Anrukinzumab: Difference between revisions
From WikiMD's Wellness Encyclopedia
CSV import Tags: mobile edit mobile web edit |
CSV import |
||
| Line 58: | Line 58: | ||
{{monoclonal-antibody-stub}} | {{monoclonal-antibody-stub}} | ||
{{dictionary-stub1}} | {{dictionary-stub1}} | ||
{{No image}} | |||
Revision as of 06:36, 10 February 2025
| Anrukinzumab | |
|---|---|
| [[File:|frameless|220px|alt=|]] | |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | 910649-32-0 |
| PubChem | |
| DrugBank | |
| ChemSpider | none |
| KEGG | |
Anrukinzumab (IMA-638<ref name="IMA-638">
Wyeth.com | Complete Project Listing(link). {{{website}}}. Wyeth.
</ref>) is a humanized monoclonal antibody designed for the treatment of asthma.<ref>Statement On A Nonproprietary Name Adopted By The USAN Council: Anrukinzumab, American Medical Association.</ref>
Anrukinzumab was developed by Wyeth.
References
<references/>
| Interleukin receptor modulators | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
This article is a monoclonal antibody–related stub. You can help WikiMD by expanding it!
